search
Back to results

BEtter Control of Blood Pressure in Hypertensive pAtients Monitored Using the HOTMAN® sYstem (BEAUTY)

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Integrated hemodynamic management (IHM) - HOTMAN System
Non Integrated Hemodynamic Management (Non-IHM) - HOTMAN System
Sponsored by
Hemo Sapiens, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring HOTMAN System, Hemodynamic integrated management

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patients of either sex presenting with essential hypertension
  • having sustained hypertension both at office BP (SBP>140 mmHg) and at ABPM (SBP>135 mmHg daytime)
  • treated with 2 to 4 antihypertensive drugs
  • aged ≥ 18 and ≤ 75 years
  • after signature of the Informed Consent Form (ICF)

Exclusion Criteria:

  • pregnant or lactating female
  • type 1 diabetes
  • patients with pacemaker (ventricular/dual chamber)
  • Severe aortic insufficiency
  • severe hypertension (SBP ≥ 180 mmHg and/or DBP ≥110 mmHg)
  • resistant hypertension requiring at least 5 antihypertensive drugs
  • secondary hypertension of any aetiology, such as renal disease, pheocromocytoma, or Cushing's syndrome
  • serious disorders which may limit the ability to evaluate the efficacy or safety of the protocol, including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine, metabolic (criteria for metabolic syndrome), haematological, oncological, neurological, or psychiatric diseases
  • history of the following pathologies within the last 6 months:
  • myocardial infarction
  • unstable angina pectoris
  • percutaneous coronary intervention
  • bypass surgery
  • congestive heart failure stage III-IV
  • left branch bundle block
  • atrial fibrillation
  • hypertensive encephalopathy
  • stroke
  • extreme obesity (BMI > 35)
  • previously enrolled subjects
  • alcohol or drug abuse in the past 2 years
  • planned hospitalization during the study period
  • participation in any other clinical study within 30 days prior to screening visit

Sites / Locations

  • Tallinn Hypertension Excellence Centre
  • Hôpital européen Georges Pompidou
  • Milano Hypertension Excellence Center
  • University of Oslo, Ullevaal Hospital
  • Hypertension Unit, Dpt of Hypertension and diabetology, Medical University of Gdansk

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

HOTMAN-driven therapeutic approach arm

Control arm

Arm Description

"Hotman-driven" therapeutic approach arm(group IHM) will receive treatment according to the results of the HOTMAN® System.

Control arm will receive usual antihypertensive care according to the 2007 ESH Guidelines.

Outcomes

Primary Outcome Measures

Absolute change in daytime SBP, under ambulatory conditions (ABPM) after a 6 months follow-up.
Absolute change in daytime SBP, under ambulatory conditions (ABPM) after 6 months follow-up.

Secondary Outcome Measures

The percentage of normalization of SBP (<135 mmHg) at ABPM
The percentage of normalization of SBP (<135 mmHg) at ABPM
The absolute change from baseline in 24h SBP-ABPM, in 24h DBP-ABPM
The absolute change from baseline in 24h SBP-ABPM, in 24h DBP-ABPM
Rate of side effects
Rate of side effects
The normalization of hemodynamics (CI, HR and SSVRI), the normalization of PWV and central BP
The normalization of hemodynamics (CI, HR and SSVRI), the normalization of PWV and central BP

Full Information

First Posted
November 28, 2011
Last Updated
March 23, 2015
Sponsor
Hemo Sapiens, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01482364
Brief Title
BEtter Control of Blood Pressure in Hypertensive pAtients Monitored Using the HOTMAN® sYstem
Acronym
BEAUTY
Official Title
BEtter Control of Blood Pressure in Hypertensive pAtients Monitored Using the BEtter Control of Blood Pressure in Hypertensive pAtients Monitored Using the HOTMAN® sYstem
Study Type
Interventional

2. Study Status

Record Verification Date
November 2011
Overall Recruitment Status
Completed
Study Start Date
October 2011 (undefined)
Primary Completion Date
June 2013 (Actual)
Study Completion Date
January 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hemo Sapiens, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to demonstrate that monitoring hemodynamic parameters and then applying a predefined algorithm of drug selection (i.e. integrated hemodynamic management - IHM) improves the control of systolic blood pressure (SBP) at ambulatory blood pressure monitoring (ABPM) in hypertensive patients, as compared to classical drug selection (i.e. without IHM) during a 6 months intensive treatment program.
Detailed Description
Early BP control in hypertensives guarantees the best prevention of cardiovascular events on the long term (2007 ESH-ESC Guidelines on the Management of Hypertension; VALUE study). However, in spite of education efforts and antihypertensive drugs, blood pressure control rates remain low. The most common cause of uncontrolled BP is inadequate pharmacological treatment, because the selection of antihypertensive agents is often done independently of the hemodynamic status of the patient (volemia, peripheral resistance, cardiac inotropy, heart rate). Several studies confirmed the value of using impedance cardiography (ICG)-derived hemodynamic data as an adjunct to therapeutic decision-making in the treatment of hypertension. Working hypothesis: when it is possible to assess the hemodynamic status, and select accordingly the most appropriate pharmacological class of antihypertensive treatment, BP reduction occurs to a greater extent and more rapidly. In the present study an integrated therapeutic approach (IHM-Integrated Hemodynamic Management)was applied, aiming at detecting permanent vasoconstriction and/or hypervolemia and/or hyperinotropy through the HOTMAN System, in order to select the most appropriate antihypertensive drugs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
HOTMAN System, Hemodynamic integrated management

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
183 (Actual)

8. Arms, Groups, and Interventions

Arm Title
HOTMAN-driven therapeutic approach arm
Arm Type
Experimental
Arm Description
"Hotman-driven" therapeutic approach arm(group IHM) will receive treatment according to the results of the HOTMAN® System.
Arm Title
Control arm
Arm Type
Placebo Comparator
Arm Description
Control arm will receive usual antihypertensive care according to the 2007 ESH Guidelines.
Intervention Type
Device
Intervention Name(s)
Integrated hemodynamic management (IHM) - HOTMAN System
Intervention Description
Therapeutic approach according to HOTMAN System measurement(ICG)results .
Intervention Type
Device
Intervention Name(s)
Non Integrated Hemodynamic Management (Non-IHM) - HOTMAN System
Intervention Description
Therapeutic approach according to 2007 ESH Guidelines, regardeless HOTMAN results.
Primary Outcome Measure Information:
Title
Absolute change in daytime SBP, under ambulatory conditions (ABPM) after a 6 months follow-up.
Description
Absolute change in daytime SBP, under ambulatory conditions (ABPM) after 6 months follow-up.
Time Frame
baseline and after 6 months of treatment
Secondary Outcome Measure Information:
Title
The percentage of normalization of SBP (<135 mmHg) at ABPM
Description
The percentage of normalization of SBP (<135 mmHg) at ABPM
Time Frame
baseline and after 6 months of treatment
Title
The absolute change from baseline in 24h SBP-ABPM, in 24h DBP-ABPM
Description
The absolute change from baseline in 24h SBP-ABPM, in 24h DBP-ABPM
Time Frame
baseline and after 6 months of treatment
Title
Rate of side effects
Description
Rate of side effects
Time Frame
from baseline to 6 months of treatment
Title
The normalization of hemodynamics (CI, HR and SSVRI), the normalization of PWV and central BP
Description
The normalization of hemodynamics (CI, HR and SSVRI), the normalization of PWV and central BP
Time Frame
baseline and after 6 months of treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients of either sex presenting with essential hypertension having sustained hypertension both at office BP (SBP>140 mmHg) and at ABPM (SBP>135 mmHg daytime) treated with 2 to 4 antihypertensive drugs aged ≥ 18 and ≤ 75 years after signature of the Informed Consent Form (ICF) Exclusion Criteria: pregnant or lactating female type 1 diabetes patients with pacemaker (ventricular/dual chamber) Severe aortic insufficiency severe hypertension (SBP ≥ 180 mmHg and/or DBP ≥110 mmHg) resistant hypertension requiring at least 5 antihypertensive drugs secondary hypertension of any aetiology, such as renal disease, pheocromocytoma, or Cushing's syndrome serious disorders which may limit the ability to evaluate the efficacy or safety of the protocol, including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine, metabolic (criteria for metabolic syndrome), haematological, oncological, neurological, or psychiatric diseases history of the following pathologies within the last 6 months: myocardial infarction unstable angina pectoris percutaneous coronary intervention bypass surgery congestive heart failure stage III-IV left branch bundle block atrial fibrillation hypertensive encephalopathy stroke extreme obesity (BMI > 35) previously enrolled subjects alcohol or drug abuse in the past 2 years planned hospitalization during the study period participation in any other clinical study within 30 days prior to screening visit
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephane Laurent
Organizational Affiliation
Hopital europeen Georges Pompidou
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tallinn Hypertension Excellence Centre
City
Tallin
Country
Estonia
Facility Name
Hôpital européen Georges Pompidou
City
Paris
Country
France
Facility Name
Milano Hypertension Excellence Center
City
Milano
Country
Italy
Facility Name
University of Oslo, Ullevaal Hospital
City
Oslo
Country
Norway
Facility Name
Hypertension Unit, Dpt of Hypertension and diabetology, Medical University of Gdansk
City
Gdansk
Country
Poland

12. IPD Sharing Statement

Citations:
PubMed Identifier
26485460
Citation
Fadl Elmula FE, Rebora P, Talvik A, Salerno S, Miszkowska-Nagorna E, Liu X, Heinpalu-Kuum M, Comotti T, Larstorp AC, Rostrup M, Swierblewska E, Valsecchi MG, Kjeldsen SE, Viigimaa M, Narkiewicz K, Parati G, Laurent S; BEtter control of blood pressure in hypertensive pAtients monitored Using the HOTMAN sYstem (BEAUTY) Study Investigators. A randomized and controlled study of noninvasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients. J Hypertens. 2015 Dec;33(12):2534-45. doi: 10.1097/HJH.0000000000000749.
Results Reference
derived

Learn more about this trial

BEtter Control of Blood Pressure in Hypertensive pAtients Monitored Using the HOTMAN® sYstem

We'll reach out to this number within 24 hrs